

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 24, 2005, 14:36:22 ; Search time 151 Seconds
(without alignments)
919.392 Million cell updates/sec

Title: US-09-744-804A-78
Perfect score: 2110
Sequence: 1 MPRPRLAALCGALLCAPSL.....RLPVAHNRIRALRLRLGCG 387

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 444336

Minimum DB seq length: 0
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: A.Geneseq_23Sep04:*
2: geneseqp1980s:*
3: geneseqp1990s:*
4: geneseqp2000s:*
5: geneseqp2001s:*
6: geneseqp2002s:*
7: geneseqp2003as:*
8: geneseqp2003bs:*
9: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	54	2.6	9 3 AAY82844	Aay82844 Lactadher
2	53	2.5	9 3 AAY82840	Aay82840 Lactadher
3	49	2.3	9 3 AAY82841	Aay82841 Lactadher
4	48	2.3	9 5 ABG32319	Abg32319 HLA-A1/A2
5	46	2.2	9 3 AAY82843	Aay82843 Lactadher
6	45	2.1	9 3 AAY82842	Aay82842 Lactadher
7	45	2.1	10 6 ABJ50137	Abj50137 151P3D4 C
8	45	2.1	10 6 ABJ51815	Abj51815 151P3D4 C
9	45	2.1	10 6 ABJ40507	Abj40507 151P3D4 C
10	45	2.1	10 6 ABJ39695	Abj39695 151P3D4 C
11	45	2.1	10 6 ABJ54131	Abj54131 151P3D4 C
12	45	2.1	10 6 ABJ40876	Abj40876 151P3D4 C
13	45	2.1	10 6 ABJ53401	Abj53401 151P3D4 C
14	45	2.1	10 6 ABJ51353	Abj51353 151P3D4 C
15	45	2.1	10 6 ABJ52549	Abj52549 151P3D4 C
16	45	2.1	10 6 ABJ50895	Abj50895 151P3D4 C
17	44	2.1	9 3 AAY82846	Aay82846 Lactadher
18	44	2.1	9 3 ABJ42681	Abj42681 151P3D4 C
19	44	2.1	9 6 ABJ44746	Abj44746 151P3D4 C
20	44	2.1	9 6 ABJ44094	Abj44094 151P3D4 C
21	44	2.1	9 6 ABJ46023	Abj46023 151P3D4 C
22	44	2.1	9 6 ABJ48298	Abj48298 151P3D4 C
23	44	2.1	9 6 ABJ47602	Abj47602 151P3D4 C
24	44	2.1	9 6 ABJ41130	Abj41130 151P3D4 C
25	44	2.1	9 6 ABJ48967	Abj48967 151P3D4 C

26	44	2.1	9 6 ABJ43478	Abj43478 151P3D4 C
27	44	2.1	9 6 ABJ19878	Abj19878 MHC bind1
28	44	2.1	10 6 ABJ50787	Abj50787 151P3D4 C
29	44	2.1	10 6 ABJ40913	Abj40913 151P3D4 C
30	44	2.1	10 6 ABJ51010	Abj51010 151P3D4 C
31	44	2.1	10 6 ABJ50205	Abj50205 151P3D4 C
32	44	2.1	10 6 ABJ54067	Abj54067 151P3D4 C
33	44	2.1	10 6 ABJ50314	Abj50314 151P3D4 C
34	44	2.1	10 6 ABJ51009	Abj51009 151P3D4 C
35	44	2.1	10 6 ABJ52619	Abj52619 151P3D4 C
36	44	2.1	10 6 ABJ41328	Abj41328 151P3D4 C
37	44	2.1	10 6 ABJ40519	Abj40519 151P3D4 C
38	44	2.1	10 6 ABJ50264	Abj50264 151P3D4 C
39	44	2.1	10 6 ABJ52074	Abj52074 151P3D4 C
40	44	2.1	10 6 ABJ53479	Abj53479 151P3D4 C
41	44	2.1	10 6 ABJ51324	Abj51324 151P3D4 C
42	44	2.1	10 6 ABJ52807	Abj52807 151P3D4 C
43	44	2.1	10 6 ABJ41714	Abj41714 151P3D4 C
44	44	2.1	10 6 ABJ53219	Abj53219 151P3D4 C
45	44	2.1	10 6 ABJ54066	Abj54066 151P3D4 C

ALIGNMENTS

RESULT 1	AAY82844	standard; peptide; 9 AA.
ID	AAY82844	
AC	AAY82844;	
DT	19-JUN-2000 (first entry)	
XX		
DE	Lactadherin (BA-46) peptide fragment (tumour associated antigen).	
XX		
KW	Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment; prevention; cure; anti-tumour vaccine; metastases; breast; bladder;	
KW	prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;	
KW	MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;	
KW	prostate specific antigen; prostate specific membrane antigen;	
KW	prostate acid phosphatase; mucin; lactadherin;	
KW	teratocarcinoma derived growth factor; PSA; PSMa; PAP; CRIPTO-1.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200006723-A1.	
XX		
PD	10-FEB-2000.	
XX		
PF	29-JUL-1999; 99WO-IL000417.	
XX		
PR	30-JUL-1998; 98IL-00125608.	
XX		
PA	(YEDA) YEDA RES & DEV CO LTD.	
PA	(BIOT-) BIO-TECHNOLOGY GEN CORP.	
XX		
PI	Bisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Frickin M;	
PI	Fitzner-Mctas C;	
XX		
DR	WPI; 2000-205463/18.	
XX		
PT	Tumour associated antigen peptides, especially derived from uroplakin,	
PT	useful as vaccines to prevent or cure cancers including breast, bladder,	
PT	prostate, pancreas, ovary, thyroid, colon and stomach.	
XX		
PS	Claim 17; Page 100; 113pp; English.	
XX		
CC	Tumour associated antigen peptides (TAA) may be used for the treatment,	
CC	prevention and cure of cancer or cancer metastases. The cancer may be	
CC	breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head	
CC	or neck cancer or a carcinoma. The tumour associated antigens are	
CC	presentable to the immune system by HLA-A2 molecules and are generally	
CC	between 8 to 10 amino acids in length. The amino acids located at	

CC presentable to the immune system by HLA-A2 molecules and are generally
CC between 8 to 10 amino acids in length. The amino acids located at
CC positions 2 and 9 of the tumour associated antigens are the anchor
CC residues which participate in the binding to MHC class I molecules, more
CC specifically HLA-A2. More tumour associated antigens are described in
CC GENESEQ records AAY82806-Y82882. Those tumour associated antigens
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and
CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from
CC prostate specific antigen (PSA). Those described in records AAY82830-
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those
CC described in records Y82836-AAY82839 are derived from prostate acid
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived
CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are
CC derived from Mucin and those described in records AAY82871-Y82882 are
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;
SQ

Query Match 2.3%; Score 49; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 131 NLRRMWT 139
Db 1 NLRRMWT 9

RESULT 4
ABG32319
ID ABG32319 standard; peptide; 9 AA.
XX ABG32319;
AC

XX 05-NOV-2002 (first entry)
DT
XX
XX HLA-A1/A2 associated immunogenic peptide from human MFG-E8.
DE
XX
XX Human; immunogen; epitope; HLA-A1; human leukocyte antigen; CTL;
KW cytotoxic Y lymphocyte; cytotoxic; cancer; colorectal carcinoma;
KW ovarian carcinoma; lung carcinoma; prostate carcinoma; vaccine; tumour;
KW HLA-2; passive immunotherapy; MFG-E8; milk fat globule glycoprotein E8.
XX
XX Homo sapiens.
OS
XX
XX MO200246416-A2.
PN
XX
XX 13-JUN-2002.
PD
XX
XX 04-DEC-2001; 2001MO-US047290.
PF
XX
XX 04-DEC-2000; 2000US-0251022P.
PR
XX 20-DEC-2000; 2000US-0256824P.
PR
XX
XX (ARGO-) ARGONEX INC.
PA
XX
XX Ramakrishna V, Ross M, Philip R;
PI
XX
XX WPI; 2002-619021/66.
DR
XX
XX New immunogen useful as a vaccine for inducing cytotoxic T-lymphocyte,
PT and for diagnosing, preventing or treating cancer e.g. ovarian carcinoma.
PT
XX
XX Claim 1; Page 50; 60pp; English.
PS
XX
XX The invention relates to an immunogen comprising an isolated polypeptide
CC whose amino acid sequence comprises an epitopic peptide, does not include
CC MAGE 4 or MFG-E8 proteins, or consists of MAGE D protein or its
CC immunologically active fragment. Also included are a polynucleotide
CC encoding the immunogen or its complement, a vector comprising the
CC polynucleotide, a mammalian cell comprising the vector and expressing the
CC polynucleotide, a vaccine composition comprising the immunogen and an
CC antibody specific for the immunogen. The immunogen is useful for inducing

CC a cytotoxic T lymphocyte (CTL) in vitro that is specific for a tumour
CC cell expressing human leukocyte antigen (HLA)-A1 or A2. The immunogen is
CC useful for inducing a CTL response when administered to a subject. A
CC mammalian cell that can express the immunogen, is useful for inducing a
CC CTL response in vitro that is specific for a tumour cell expressing HLA-1
CC or HLA-2. The immunogen or cell is useful for inducing CTL for treating a
CC subject with cancer (carcinoma, preferably colorectal carcinoma, ovarian
CC carcinoma, lung carcinoma and prostate carcinoma). The immunogen is also
CC useful for screening and diagnostic agents, for gene screening in
CC patients afflicted with cancer, for screening a sample for the presence
CC of CTLs that specifically recognise the corresponding epitopes, as a
CC diagnostic tool to evaluate the efficacy of the immunotherapeutic
CC treatments, to prepare class I MHC (major histocompatibility class)
CC tetramers which are utilised in conjunction with flow cytometry to
CC quantitate the frequency of peptide-specific CTL that are present in a
CC samples of lymphocytes from an individual, and for stimulating the
CC production of antibodies for use in passive immunotherapy, for use as
CC diagnostic reagents, and for use as reagents in other processes such as
CC affinity chromatography. The present sequence is an immunogenic epitope
CC of the invention derived from human MFG-E8 (milk fat globule glycoprotein
CC E8

XX Sequence 9 AA;
SQ

Query Match 2.3%; Score 48; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 152 HEYLKAFKV 160
Db 1 HEYLKAFKV 9

RESULT 5
AAY82843
ID AAY82843 standard; peptide; 9 AA.
XX AAY82843;
AC

XX 19-JUN-2000 (first entry)
DT
XX
XX Lactadherin (BA-46) peptide fragment (tumour associated antigen).
DE
XX
XX Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;
KW prevention; cure; anti-tumour vaccine; metatases; breast; bladder;
KW prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;
KW MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;
KW prostate specific antigen; prostate specific membrane antigen;
KW prostate acid phosphatase; mucin; lactadherin;
KW Teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.
XX
XX Homo sapiens.
OS
XX
XX MO200006723-A1.
PN
XX
XX 10-FEB-2000.
PD
XX
XX 29-JUL-1999; 99MO-II000417.
PF
XX 30-JUL-1998; 98IL-00125608.
PR
XX
XX (YEDA) YEDA RES & DEV CO LTD.
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
PA
XX
XX Eisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M;
PI Fitzer-Altas C;
PI
XX
XX WPI; 2000-205463/18.
DR
XX
XX Tumour associated antigen peptides, especially derived from uroplakin,
PT useful as vaccines to prevent or cure cancers including breast, bladder,
PT prostate, pancreas, ovary, thyroid, colon and stomach.
PT
XX

PS Claim 17; Page 100; 113pp; English.

XX Tumour associated antigen peptides (TAA) may be used for the treatment,
XX prevention and cure of cancer or cancer metastases. The cancer may be
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head
CC or neck cancer or a carcinoma. The tumour associated antigens are
CC presentable to the immune system by HLA-A2 molecules and are generally
CC between 8 to 10 amino acids in length. The amino acids located at
CC positions 2 and 9 of the tumour associated antigens are the anchor
CC residues which participate in the binding to MHC class I molecules, more
CC specifically HLA-A2. More tumour associated antigens are described in
CC GENESEQ records AAY82806-Y82882. Those tumour associated antigens
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and
CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from
CC prostate specific antigen (PSA). Those described in records AAY82830-
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those
CC described in records Y82836-AAY82839 are derived from prostate acid
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived
CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are
CC derived from Mucin and those described in records AAY82871-Y82882 are
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;

Query Match 2.2%; Score 46; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 194 NLFETPVEA 202
|||
1 NLFETPVEA 9

RESULT 6
AAY82842
ID AAY82842 standard; peptide; 9 AA.
XX
AC AAY82842;
XX

DT 19-UUN-2000 (first entry)
XX

DE Lactadherin (BA-46) peptide fragment (tumour associated antigen).
XX

XX Tumour associated antigen peptide; TAA; cancer; carcinoma; treatment;
KM prevention; cure; anti-tumour vaccine; metastases; breast; bladder;
KM prostate; pancreas; ovary; thyroid; colon; stomach; carcinoma;
KM MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;
KM prostate specific antigen; prostate specific membrane antigen;
KM prostate acid phosphatase; mucin; lactadherin;
KM teratocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1.
XX

XX Homo sapiens.
XX

OS
XX
PN WO200006723-A1.
XX

PD 10-FEB-2000.
XX

PF 29-JUL-1999; 99WO-IL000417.
XX

PR 30-JUL-1998; 98IL-00125608.
XX

XX (YEDA) YEDA RES & DEV CO LTD.
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX

XX Eisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M,
PI Fitzer-Altas C;
XX

XX WPI; 2000-205463/18.
XX

PT Tumor associated antigen peptides, especially derived from uroplakin,
PT useful as vaccines to prevent or cure cancers including breast, bladder,
PT prostate, pancreas, ovary, thyroid, colon and stomach.

XX Claim 17; Page 99; 113pp; English.

XX Tumour associated antigen peptides (TAA) may be used for the treatment,
XX prevention and cure of cancer or cancer metastases. The cancer may be
CC breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head
CC or neck cancer or a carcinoma. The tumour associated antigens are
CC presentable to the immune system by HLA-A2 molecules and are generally
CC between 8 to 10 amino acids in length. The amino acids located at
CC positions 2 and 9 of the tumour associated antigens are the anchor
CC residues which participate in the binding to MHC class I molecules, more
CC specifically HLA-A2. More tumour associated antigens are described in
CC GENESEQ records AAY82806-Y82882. Those tumour associated antigens
CC described in records AAY82806-Y82824 and AAY82855-Y82869 are derived
CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and
CC Uroplakin IB. Those described in records AAY82825-Y82829 are derived from
CC prostate specific antigen (PSA). Those described in records AAY82830-
CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those
CC described in records Y82836-AAY82839 are derived from prostate acid
CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived
CC from lactadherin (BA-46). Those described in records AAY82847-Y82854 are
CC derived from Mucin and those described in records AAY82871-Y82882 are
CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)

XX Sequence 9 AA;

Query Match 2.1%; Score 45; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 356 NLFETPILA 364
|||
1 NLFETPILA 9

RESULT 7
ABJ50137
ID ABJ50137 standard; peptide; 10 AA.
XX

AC ABJ50137;
XX

DT 16-OCT-2003 (first entry)
XX

DE 151P3D4 cancer gene related HLA peptide #7957.
XX

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KM bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX

OS Homo sapiens.
XX

PN WO200283860-A2.
XX

PD 24-OCT-2002.
XX

PF 09-APR-2002; 2002WO-US011644.
XX

PR 10-APR-2001; 2001US-0282739P.
XX

PR 25-APR-2001; 2001US-0286630P.
XX

XX (AGEN-) AGENSYS INC.
PA

XX Chalilta-Eld PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX

XX WPI; 2003-167091/16.
XX

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

PS Claim 13; Page 235; 426pp; English.

XX The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a molecule that expresses the 151P3D4 protein is modulated. The novel
CC composition, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention

SQ Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 299 VTGIITQGAR 308
DB 1 VTGIITQGAK 10

RESULT 8
ABJ51815
ID ABJ51815 standard; peptide; 10 AA.
AC ABJ51815;
XX
XX
XX 16-OCT-2003 (first entry)
DT
DE 151P3D4 cancer gene related HLA peptide #9635.

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KM bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
XX Homo sapiens.

XX WO200283860-A2.

PD 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX (AGEN-) AGENSYS INC.

XX PA Challita-Eld PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
XX WPI; 2003-167091/16.

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

PS Claim 13; Page 251; 426pp; English.

XX The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a molecule that expresses the 151P3D4 protein is modulated. The novel
CC composition, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of

CC the invention

XX Sequence 10 AA;

XX Query Match 2.1%; Score 45; DB 6; Length 10;
SQ Best Local Similarity 90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 299 VTGIITQGAR 308
DB 1 VTGIITQGAK 10

RESULT 9
ABJ40507
ID ABJ40507 standard; peptide; 10 AA.
AC ABJ40507;
XX
XX 17-OCT-2003 (first entry)
DT
DE 151P3D4 cancer gene related peptide #1134.

XX Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KM bronchial; breast; carcinoma.
XX
XX Unidentified.

XX WO200283860-A2.

PN 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

XX (AGEN-) AGENSYS INC.

XX PA Challita-Eld PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
XX WPI; 2003-167091/16.

XX New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.

PS Claim 13; Page 138; 426pp; English.

XX The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a molecule that expresses the 151P3D4 protein is modulated. The novel
CC composition, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC 151P3D4 related peptide of the invention

SQ Sequence 10 AA;

Query Match 2.1%; Score 45; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 299 VTGIITQGAR 308
DB 1 VTGIITQGAK 10

```

RESULT 10
ABJ39695
ID ABJ39695 standard; peptide; 10 AA.
XX
XX
AC ABJ39695;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE 151P3D4 cancer gene related peptide #322.
XX
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma.
XX
XX
OS Unidentified.
XX
XX
PN WO200283860-A2.
XX
XX
PD 24-OCT-2002.
XX
XX
PF 09-APR-2002; 2002WO-US011644.
XX
XX
PR 10-APR-2001; 2001US-0282739P.
XX
PR 25-APR-2001; 2001US-0286630P.
XX
XX
PA (AGEN-) AGENSYS INC.
XX
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
XX
DR MPI; 2003-167091/16.
XX
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
XX
PS Claim 13; Page 130; 426pp; English.
XX
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC 151P3D4 related peptide of the invention
XX
XX
SQ Sequence 10 AA;
XX
XX
Query Match 2.1%; Score 45; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX
QY 299 VTGIITOGAR 308
1 VTGIITOGAK 10
XX
XX
DB 1 VTGIITOGAK 10
XX
XX
RESULT 11
ABJ54131
ID ABJ54131 standard; peptide; 10 AA.
XX
XX
AC ABJ54131;
XX
XX
DT 16-OCT-2003 (first entry)
XX
XX
DE 151P3D4 cancer gene related HLA peptide #11951.
XX
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;

```

```

KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200283860-A2.
XX
XX
PD 24-OCT-2002.
XX
XX
PF 09-APR-2002; 2002WO-US011644.
XX
XX
PR 10-APR-2001; 2001US-0282739P.
XX
PR 25-APR-2001; 2001US-0286630P.
XX
XX
PA (AGEN-) AGENSYS INC.
XX
XX
PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
PI Morrison RK, Ge W, Jakobovits A;
XX
XX
DR MPI; 2003-167091/16.
XX
XX
PT New 151P3D4 proteins and genes, useful for eliciting a humoral or
PT cellular immune response, or for diagnosing, prognosing, preventing or
PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
PT or carcinoma.
XX
XX
PS Claim 13; Page 273; 426pp; English.
XX
XX
CC The invention relates to a novel composition comprising a substance that
CC modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or
CC a molecule that is modulated by the 151P3D4 protein, where the status of
CC a cell that expresses the 151P3D4 protein is modulated. The novel
CC compositions, or the 151P3D4 proteins and genes, are useful for eliciting
CC a humoral or cellular immune response. The 151P3D4 genes and proteins
CC are also useful for diagnosing, prognosing, preventing or treating
CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
CC human leukocyte antigen peptide relating to the 151P3D4 composition of
CC the invention
XX
XX
SQ Sequence 10 AA;
XX
XX
Query Match 2.1%; Score 45; DB 6; Length 10;
Best Local Similarity 90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX
QY 299 VTGIITOGAR 308
1 VTGIITOGAK 10
XX
XX
DB 1 VTGIITOGAK 10
XX
XX
RESULT 12
ABJ40876
ID ABJ40876 standard; peptide; 10 AA.
XX
XX
AC ABJ40876;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE 151P3D4 cancer gene related peptide #1503.
XX
XX
KW Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer;
KW cellular immune response; adenocarcinoma; bladder; colorectal; lung;
KW bronchial; breast; carcinoma.
XX
XX
OS Unidentified.
XX
XX
PN WO200283860-A2.
XX
XX
PD 24-OCT-2002.
XX
XX
PF 09-APR-2002; 2002WO-US011644.
XX

```

PT	treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer or carcinoma.
XX	Claim 13; Page 266; 426pp; English.
PS	The invention relates to a novel composition comprising a substance that modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or a molecule that is modulated by the 151P3D4 protein, where the status of a cell that expresses the 151P3D4 protein is modulated. The novel compositions, or the 151P3D4 proteins and genes, are useful for eliciting a humoral or cellular immune response. The 151P3D4 genes and proteins are also useful for diagnosing, prognosing, preventing or treating cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or bronchial cancer, breast cancer or carcinoma. This sequence represents a human leukocyte antigen peptide relating to the 151P3D4 composition of the invention
CC	Sequence 10 AA;
XX	
SQ	
Query March	2.1%; Score 45; DB 6; Length 10;
Best Local Similarity	90.0%; Pred. No. 9.3e+03;
Matches 9; Conservative	1; Mismatches 0; Indels 0; Gaps 0
Oy	299 VTGIITOGAR 308 : 1 VTGIITOGAK 10
Db	
RESULT 14	
ABJ51353	
ID	ABJ51353 standard; peptide; 10 AA.
AC	ABJ51353;
XX	
DT	16-OCT-2003 (first entry)
XX	
DE	151P3D4 cancer gene related HLA peptide #9173.
KW	Cytostatic; gene therapy; vaccine; modulator; 151P3D4; humoral; cancer; cellular immune response; adenocarcinoma; bladder; colorectal; lung; bronchial; breast; carcinoma; human leukocyte antigen; HLA.
XX	
OS	Homo sapiens.
XX	
PN	WO200283860-A2.
XX	
PD	24-OCT-2002.
PF	09-APR-2002; 2002WO-US011644.
XX	
PR	10-APR-2001; 2001US-0282739P.
PR	25-APR-2001; 2001US-0286630P.
XX	
PA	(AGEN-) AGENSYS INC.
PI	Challita-Bid PM, Raitano AB, Farris M, Hubert RS, Morrison K; Morrison RK, Ge W, Jakobovits A;
XX	
DR	WPI; 2003-167091/16.
XX	
PT	New 151P3D4 proteins and genes, useful for eliciting a humoral or cellular immune response, or for diagnosing, prognosing, preventing or treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer or carcinoma.
XX	
PS	Claim 13; Page 246; 426pp; English.
CC	The invention relates to a novel composition comprising a substance that modulates the status of a 151P3D4 protein (e.g. 151P3D4 variant 1-11; or a molecule that is modulated by the 151P3D4 protein, where the status of a cell that expresses the 151P3D4 protein is modulated. The novel compositions, or the 151P3D4 proteins and genes, are useful for eliciting a humoral or cellular immune response. The 151P3D4 genes and proteins
CC	

CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 15IP3D4 composition of
 CC the invention
 CC

XX Sequence 10 AA;
 SQ

Query Match 2.1%; Score 45; DB 6; Length 10;
 Best Local Similarity 90.0%; Pred. No. 9.3e+03;
 Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 299 VTGIITOGAR 308
 |||||
 1 VTGIITOGAK 10

Db

RESULT 15

ABJ52549
 ID ABJ52549 standard; peptide; 10 AA.

AC ABJ52549;

DT 16-OCT-2003 (first entry)

DE 15IP3D4 cancer gene related HLA peptide #10369.

KW Cytostatic; gene therapy; vaccine; modulator; 15IP3D4; humoral; cancer;
 KM cellular immune response; adenocarcinoma; bladder; colorectal; lung;
 KW bronchial; breast; carcinoma; human leukocyte antigen; HLA.

OS Homo sapiens.

PN WO200283860-A2.

PD 24-OCT-2002.

PF 09-APR-2002; 2002WO-US011644.

PR 10-APR-2001; 2001US-0282739P.

PR 25-APR-2001; 2001US-0286630P.

PA (AGEN-) AGENSYS INC.

PI Challita-Eid PM, Raitano AB, Faris M, Hubert RS, Morrison K;
 PI Morrison RK, Ge W, Jakobovits A;

DR WPI; 2003-167091/16.

PT New 15IP3D4 proteins and genes, useful for eliciting a humoral or
 PT cellular immune response, or for diagnosing, prognosing, preventing or
 PT treating cancer, e.g. adenocarcinoma, bladder cancer, lung, breast cancer
 PT or carcinoma.

PS Claim 13; Page 258; 426pp; English.

XX The invention relates to a novel composition comprising a substance that
 CC modulates the status of a 15IP3D4 protein (e.g. 15IP3D4 variant 1-11; or
 CC a molecule that is modulated by the 15IP3D4 protein, where the status of
 CC a cell that expresses the 15IP3D4 protein is modulated. The novel
 CC compositions, or the 15IP3D4 proteins and genes, are useful for eliciting
 CC a humoral or cellular immune response. The 15IP3D4 genes and proteins
 CC are also useful for diagnosing, prognosing, preventing or treating
 CC cancer, e.g. adenocarcinoma, bladder cancer, colorectal cancer, lung or
 CC bronchial cancer, breast cancer or carcinoma. This sequence represents a
 CC human leukocyte antigen peptide relating to the 15IP3D4 composition of
 CC the invention
 CC

XX Sequence 10 AA;
 SQ

Query Match 2.1%; Score 45; DB 6; Length 10;
 Best Local Similarity 90.0%; Pred. No. 9.3e+03;
 Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 299 VTGIITOGAR 308
 |||||
 1 VTGIITOGAK 10

Db

Search completed: January 24, 2005, 14:42:22
 Job time : 152 secs

Db 1 CGCRLCNP 8

RESULT 3

ID 012100 PRELIMINARY; PRT; 9 AA.
AC 012100;
DT 01-JUL-1997 (TREMBlrel. 04, Created)
DT 01-JUL-1997 (TREMBlrel. 04, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE Tat protein (Fragment).
GN Name=tat;
OS Caprine arthritis encephalitis virus (CAEV).
OS Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11660;
RN [1]
RP SEQUENCE FROM N.A.
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U81441; AAB60836.1; -.
FT NON TER 1
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;
Query Match 1.5%; Score 31; DB 2; Length 9;
Best Local Similarity 62.5%; Pred. No. 1.8e+06;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 CGALLCAP 18
Db 1 CGCRLCNP 8

RESULT 4

ID 012102 PRELIMINARY; PRT; 9 AA.
AC 012102;
DT 01-JUL-1997 (TREMBlrel. 04, Created)
DT 01-JUL-1997 (TREMBlrel. 04, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE Tat protein (Fragment).
GN Name=tat;
OS Caprine arthritis encephalitis virus (CAEV).
OS Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11660;
RN [1]
RP SEQUENCE FROM N.A.
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U81442; AAB60838.1; -.
FT NON TER 1
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;

QY 11 CGALLCAP 18
Db 1 CGCRLCNP 8

RESULT 5

ID 012104 PRELIMINARY; PRT; 9 AA.
AC 012104;
DT 01-JUL-1997 (TREMBlrel. 04, Created)
DT 01-JUL-1997 (TREMBlrel. 04, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE Tat protein (Fragment).
GN Name=tat;
OS Caprine arthritis encephalitis virus (CAEV).
OS Viruses; Retrovird viruses; Retroviridae; Lentivirus.

OX NCBI_TaxID=11660;

RN [1]
RP SEQUENCE FROM N.A.
RA Turelli P., Guiguen F., Mornex J.-F., Vigne R., Querat G.;
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U81443; AAB60840.1; -.
FT NON TER 1
SQ SEQUENCE 9 AA; 922 MW; 21E8644EB7340EB8 CRC64;

QY 11 CGALLCAP 18
Db 1 CGCRLCNP 8

RESULT 6

ID 012104 STANDARD; PRT; 9 AA.
AC 012104;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Aspartocin (Asparaglocin).
OS Squalus acanthias (Spiny dogfish).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
OC Rhamphorhynchii; Squalae; Hypnosqualea; Squaliformes; Squaloidei;
OC Squalidae; Squalus.
OX NCBI_TaxID=7797;
RN [1]
RP SEQUENCE.
RX MEDLINE=73031727; PubMed=5083097;
RA Acher R., Chauvet J., Chauvet M.-T.;
RT "Phylogeny of the neurohypophyseal hormones. Two new active peptides isolated from a cartilaginous fish, Squalus acanthias.";
RL Eur. J. Biochem. 29:12-19 (1972).
RN [2]
RP SEQUENCE.
RX MEDLINE=72128038; PubMed=4622083;
RA Acher R., Chauvet J., Chauvet M.-T., Fontaine M.;
RT "Identification of 2 new neurohypophyseal hormones, valitocin (Val8-oxytocin) and aspartocin (Asn4-oxytocin) in a selachian fish, the spiny dog-fish (Squalus acanthias).";
RL C. R. Acad. Sci., D, Sci. Nat. 274:313-316 (1972).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- SIMILARITY: Belongs to the vasopressin/oxytocin family.
DR InterPro: IPR000981; Neuhyp_horm.
DR Pfam: PF00220; Hormone_4; 1.
DR PROSITE: PS00264; NEUROHYPOPHYS_HORM, 1.
KW Annotation: Direct protein sequencing; Hormone.
FT DISULFID 1
FT MOD RES 9
SQ SEQUENCE 9 AA; 996 MW; 17F8376BB44404B CRC64;

QY 225 CEANGCANPUG 235
Db 1 CYINNC--PLG 9

RESULT 7

ID 07M4C2 PRELIMINARY; PRT; 10 AA.
AC 07M4C2;
DT 01-MAR-2004 (TREMBlrel. 26, Created)
DT 01-MAR-2004 (TREMBlrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Sperm-activating peptide (Tyr-2, Asn-3, Asp-7,10, Arg-8, Ile-9 SAP-

DE 1).
 OS Echinometra mathaei (Rock boring urchin).
 OC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;
 OC Echinoides; Echinoidea; Echinacea; Echinoida; Echinometridae;
 OC Echinometra; Echinometra; Echinometra; Echinometra;
 NCBI_TaxID=31178;
 RN [1]
 RP SEQUENCE.
 RA Yoshino K.I., Kajiyama H., Nomura K., Takao T., Shimonishi Y.,
 RA Kurita M., Yamaguchi M., Suzuki N.;
 RT "A halogenated amino acid-containing sperm activating peptide and its
 RT related peptides isolated from the egg jelly of sea urchins,
 RT Tridacna striatella, Pseudobornella maculata, Strongylocentrotus
 RT nudus, Echinometra mathaei and Heterocentrotus mammillatus.";
 RL Comp. Biochem. Physiol. 94:739-751(1989).
 DR PIR, G60589; G60589.
 SQ SEQUENCE 10 AA; 1136 MW; 128ADFOA8744724 CRC64;

Query Match 1.4%; Score 29; DB 2; Length 10;
 Best Local Similarity 55.6%; Pred. No. 6.7e+04;
 Matches 5; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 162 YSLNGHEPD 170
 Db 2 YNLNGDRID 10

RESULT 8
 LCK6_LEUMA STANDARD; PRT; 8 AA.

AC P19988;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Leucokinin VI (L-VI).
 OS Leucophaea maderae (Madeira cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota;
 OC Neoptera; Orthoptera; Dictyoptera; Blattaria; Blaberidae;
 OC Blaberidae; Leucophaea.
 NCBI_TaxID=6988;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Head;
 RX MEDLINE=87052651; PubMed=2877794;
 RA Holman G.M., Cook B.J., Nachman R.J.;
 RT "Isolation, primary structure, and synthesis of leucokinin V and VI:
 RT myotropic peptides of Leucophaea maderae.";
 RL Comp. Biochem. Physiol. 88C:27-30(1987).
 CC -1- FUNCTION: This cephalomyotropic peptide stimulates contractile
 CC activity of cockroach proctodeum (hindgut).
 CC -1- SUBCELLULAR LOCATION: Secreted.
 DR PIR, JS0316; JS0316.
 KW Amidation; Direct protein sequencing; Neuropeptide;
 KM Pyroglutamate carboxylic acid.
 FT MOD_RES 1 1 Glycine amide.
 FT MOD_RES 8 8 Glycine amide.
 SQ SEQUENCE 8 AA; 935 MW; 9D635B1E9D5A5A6 CRC64;

Query Match 1.3%; Score 28; DB 1; Length 8;
 Best Local Similarity 57.1%; Pred. No. 1.8e+06;
 Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 250 SSYKTVG 256
 Db 2 SSFHSWG 8

RESULT 9
 O9GKI4 PRELIMINARY; PRT; 10 AA.
 AC O9GKI4;
 DT 01-MAR-2001 (TEMBLrel. 16, Created)
 DT 01-MAR-2001 (TEMBLrel. 16, Last sequence update)

DT 01-DEC-2001 (TEMBLrel. 19, Last annotation update)
 DE Fragile X mental retardation 1 protein (Fragment).
 GN Name=Fmr1;
 OS Macaca arctoides (Stump-tailed macaque).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
 OC Cercopithecinae; Macaca.
 NCBI_TaxID=9540;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21264938; PubMed=11058604;
 RA Kumari D., Usdin K.;
 RT "Interaction of the transcription factors USF1, USF2, and alpha -
 RT Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental
 RT retardation syndrome.";
 RL J. Biol. Chem. 276:4357-4364(2001).
 DR EMBL, AF251350; AAC44599.1; -.
 FT NON_TER 10 10
 SQ SEQUENCE 10 AA; 1160 MW; 7C2A2BCB02D2C72B CRC64;

Query Match 1.3%; Score 28; DB 2; Length 10;
 Best Local Similarity 66.7%; Pred. No. 8.1e+04;
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 39 EEISOEVVG 47
 Db 2 BELVEVRG 10

RESULT 10
 O9GKI5 PRELIMINARY; PRT; 10 AA.

AC O9GKI5;
 DT 01-MAR-2001 (TEMBLrel. 16, Created)
 DT 01-MAR-2001 (TEMBLrel. 16, Last sequence update)
 DT 01-DEC-2001 (TEMBLrel. 19, Last annotation update)
 DE Fragile X mental retardation 1 protein (Fragment).
 GN Name=Fmr1;
 OS Pan troglodytes (Chimpanzee).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
 NCBI_TaxID=9598;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21264938; PubMed=11058604;
 RA Kumari D., Usdin K.;
 RT "Interaction of the transcription factors USF1, USF2, and alpha -
 RT Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental
 RT retardation syndrome.";
 RL J. Biol. Chem. 276:4357-4364(2001).
 DR EMBL, AF251349; AAC44598.1; -.
 FT NON_TER 10 10
 SQ SEQUENCE 10 AA; 1160 MW; 7C2A2BCB02D2C72B CRC64;

Query Match 1.3%; Score 28; DB 2; Length 10;
 Best Local Similarity 66.7%; Pred. No. 8.1e+04;
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 39 EEISOEVVG 47
 Db 2 BELVEVRG 10

RESULT 11
 OXVA_SCYCA STANDARD; PRT; 9 AA.
 ID OXVA_SCYCA
 AC P42956;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Aavatochin.
 OS Scyliorhinus canicula (Spotted dogfish) (Spotted catshark).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;

OC Elasmobranchii; Galeomorphii; Galeoidea; Carcharhiniformes;
 OC Scyliorhinidae; Scyliorhinus.
 OC NCB1_TaxID=7830;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Pituitary;
 RX MEDLINE=95062247; PubMed=7972045;
 RA Chauvet J., Rouille Y., Chauvet M.-T., Acher R.;
 RT "Special evolution of neurohypophyseal hormones in cartilaginous
 fishes: aspartic acid and phasvotocin, two oxytocin-like peptides isolated
 from the spotted dogfish (Scyliorhinus caniculus).";
 RL Proc. Natl. Acad. Sci. U.S.A. 91:11266-11270(1994).
 CC -1- FUNCTION: Displays oxytocic activity on rat uterus.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- SIMILARITY: Belongs to the vasopressin/oxytocin family.
 DR InterPro: IPR000981; Neurohyp. horm.
 DR Pfam: PF002220; Hormone_4; 1.
 DR PROSITE: PS00264; NEUROHYPOPHYS. HORM.; 1.
 KW Amidation; Direct protein sequencing; Hormone.
 FT DISULFID 1
 FT MOD RES 9 9
 SQ SEQUENCE 9 AA; 982 MW; 17EDD76BB44404B CRC64;
 Query Match 1.3%; Score 27; DB 1; Length 9;
 Best Local Similarity 45.5%; Pred. No. 1.8e+06;
 Matches 5; Conservative 2; Mismatches 2; Indels 2; Gaps 1;
 Oy 225 CEINGANPLG 235
 Db 1 CYINNC-PVG 9
 RESULT 12
 Q7M4O9 PRELIMINARY; PRT; 9 AA.
 AC Q7M4O9;
 DT 01-MAR-2004 (TREMBLrel. 26, Created)
 DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update)
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
 DE Octamer-binding protein, Ku-like, 83K chain (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OC NCB1_TaxID=9606;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=91131605; PubMed=1993678;
 RA May G., Sutton C., Gould H.;
 RT "Purification and characterization of Ku-2, an octamer-binding protein
 related to the autoantigen Ku.";
 RL J. Biol. Chem. 266:3052-3059(1991).
 DR PIR; B39504; B39504.
 FT NON_TER 9 9
 SQ SEQUENCE 9 AA; 1096 MW; C65D4AAB144699D2 CRC64;
 Query Match 1.3%; Score 27; DB 2; Length 9;
 Best Local Similarity 80.0%; Pred. No. 1.8e+06;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Oy 122 NDDNP 126
 Db 5 NEDNP 9
 RESULT 13
 FAR2_ASCSU STANDARD; PRT; 7 AA.
 AC F31890;
 DT 01-JUL-1993 (Rel. 26, Created)
 DT 01-JUL-1993 (Rel. 26, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE FMRamide-like neuropeptide AF2.
 OS Ascaris suum (Pig roundworm) (Ascaris lumbricoides), and

OS Panagrellus redivivus.
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Ascaridida; Ascaridoidea;
 OC Ascarididae; Ascaris.
 OC NCB1_TaxID=6253, 6233;
 RN [1]
 RP SEQUENCE.
 RC SPECIES=A.suum;
 RX MEDLINE=93324431; PubMed=8332542;
 RA Cowden C., Stretton A.O.W.;
 RT "AF2, an Ascaris neuropeptide: isolation, sequence, and bioactivity.";
 RL Peptides 14:423-430(1993).
 RN [2]
 RP SEQUENCE.
 RC SPECIES=P.redivivus;
 RX MEDLINE=95060998; PubMed=7970891;
 RA Maule A.G., Shaw C., Bowman J.W.;
 RT "The FMRamide-like neuropeptide AF2 (Ascaris suum) is present in the
 free-living nematode, Panagrellus redivivus (Nematoda, Rhabditida).";
 RL Parasitology 109:351-356(1994).
 CC -1- FUNCTION: Has effects on muscle tension.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- TISSUE SPECIFICITY: Found in the nerve cords and a variety of
 ganglia particularly in the anterior regions.
 CC -1- SIMILARITY: Belongs to the FARP (FMRamide related peptide)
 family.
 KW Amidation; Direct protein sequencing; Neuropeptide.
 FT MOD RES 7 7
 SQ SEQUENCE 7 AA; 992 MW; 69D4073B5B1E350 CRC64;
 Query Match 1.2%; Score 26; DB 1; Length 7;
 Best Local Similarity 80.0%; Pred. No. 1.8e+06;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Oy 152 HEXLK 156
 Db 2 HEXLR 6
 RESULT 14
 PK2_PERAM STANDARD; PRT; 8 AA.
 AC P82686;
 DT 05-JUL-2004 (Rel. 44, Created)
 DT 05-JUL-2004 (Rel. 44, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Kinin-2 (Pea-K-2).
 OS Periplaneta americana (American cockroach).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattellidae;
 OC Blattidae; Periplaneta.
 OC NCB1_TaxID=6978;
 RN [1]
 RP SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND AMIDATION.
 RC TISSUE=Corpora cardiaca;
 RX MEDLINE=98010462; PubMed=9350979;
 RA Predel R., Kellner R., Rapus J., Penzlin H., Gade G.;
 RT "Isolation and structural elucidation of eight kinins from the
 retrocerebral complex of the American cockroach, Periplaneta
 americana.";
 RL Regul. Pept. 71:199-205(1997).
 CC -1- FUNCTION: Mediates visceral muscle contractile activity (myotropic
 activity).
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- MASS SPECTROMETRY: MW=855.04; METHOD=Electrospray; RANGE=1-8;
 CC NOTE=Ref.1.
 CC -1- SIMILARITY: Belongs to the kinin family.
 KW Amidation; Direct protein sequencing; Neuropeptide.
 FT MOD RES 8 8
 SQ SEQUENCE 8 AA; 856 MW; DC6365A5B9D5BD4 CRC64;
 Query Match 1.2%; Score 26; DB 1; Length 8;
 Best Local Similarity 42.9%; Pred. No. 1.8e+06;
 Matches 3; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 250 SSYKTMG 256
 :|:|:
 DB 2 ASFSWG 8

RESULT 15

TALL_PICJA STANDARD; PRT; 9 AA.
 AC p17470;
 DT 01-AUG-1990 (Rel. 15, Created)
 DT 01-AUG-1990 (Rel. 15, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE Transaldolase I (EC 2.2.1.2) (Fragment).
 OS Pichia jadinii (Yeast) (Candida utilis).
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 OC Saccharomycetales; Saccharomycetaceae; Pichia.
 OX NCBI_TaxID=4903;
 RN [1]
 RP SEQUENCE.
 RX MEDLINE=7110646; Pubmed=556924;
 RA Sun S.C., Joris L., Teolac O.;
 RT "Purification of crystallization of transaldolase isozyme I and
 RT evidence for different genetic origin of isozymes I and III in Candida
 RT utilis.";
 RL Arch. Biochem. Biophys. 178:69-78(1977).
 CC -1- FUNCTION: Transaldolase is important for the balance of
 CC metabolites in the pentose-phosphate pathway.
 CC -1- CATALYTIC ACTIVITY: Sedoheptulose 7-phosphate + D-glyceraldehyde
 CC 3-phosphate = D-erythrose 4-phosphate + D-fructose 6-phosphate.
 CC -1- PATHWAY: Pentose phosphate pathway; nonoxidative part.
 CC -1- SIMILARITY: Belongs to the transaldolase family. Subfamily 1.
 DR PIR: A12872; A12872.
 DR InterPro: IPR001585; Transaldolase.
 DR PROSITE: PS01054; TRANSALDOLASE_1; PARTIAL.
 DR PROSITE: PS00958; TRANSALDOLASE_2; PARTIAL.
 DR Direct protein sequencing; Pentose shunt; Transferrase.
 FT NON_TER 1 9
 FT NON_TER 1 9
 SQ SEQUENCE 9 AA, 1008 MW, 274F31AF0EB1E058 CRC64;

Query Match 1.24; Score 26; DB 1; Length 9;
 Best Local Similarity 66.74; Pred. No. 1.8e+06;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 OY 63 GNHGCT 68
 :|:|:
 DB 2 GHHCBT 7

Search completed: January 24, 2005, 14:39:44
 Job time : 193 secs

This Page Blank (uspto)

33 Junk (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: January 24, 2005, 14:36:23 ; Search time 39 Seconds
(without alignments)
954.766 Million cell updates/sec

Title: US-09-744-804a-78

Perfect score: 2110

Sequence: 1 MRPRLALALGALCAPSL.....RIPVAMHNRALRLGLGC 387

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 1102

Minimum DB seq length: 0
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	36	1.7	7	2 E48394	glycoprotein compo
2	33	1.6	7	2 B48394	major fat-globule
3	29	1.4	6	2 H48394	glycoprotein compo
4	29	1.4	10	2 G60589	sperm-activating p
5	28	1.3	8	2 JS0316	leucokinin VI - Ma
6	28	1.3	10	2 S65385	cytochrome-c oxida
7	27	1.3	9	2 B39504	octamer-binding pr
8	26	1.2	9	2 A12872	transaldolase (EC
9	26	1.2	10	2 PX0030	triacylglycerol li
10	25	1.2	5	2 JH0253	gut pentapeptide -
11	25	1.2	8	2 PT0691	T-cell receptor be
12	25	1.2	8	2 S19288	acylase - Kluysera
13	25	1.2	8	2 JS0315	leucokinin V - Mad
14	25	1.2	8	2 A41117	acetylcholinestera
15	25	1.2	9	2 S07241	litorin - Rohde's
16	25	1.2	9	2 A11497	transaldolase (EC
17	25	1.2	10	2 PQ0753	beta-fructofuranos
18	25	1.2	10	2 A40753	aldehyde ferredoxi
19	24.5	1.2	9	2 A24244	adipokinetic hormo
20	24.5	1.2	9	2 PT0562	T-cell receptor be
21	24	1.1	7	2 PD0029	lev-kinin 1 - pena
22	24	1.1	8	2 A25836	L-serine ammonia-1
23	24	1.1	9	2 A93408	oxytocin - Austral
24	24	1.1	9	2 A92774	oxytocin - spotted
25	24	1.1	9	2 A93147	oxytocin - finback
26	24	1.1	9	2 A91466	oxytocin - hippo
27	24	1.1	9	2 B90667	oxytocin - rabbit
28	24	1.1	10	1 RHPSG	gonadoliberin - pi
29	24	1.1	10	1 RHSHG	gonadoliberin - sh

30	24	1.1	10	1 A61126	gonadoliberin - sp
31	24	1.1	10	1 RHAQ1	gonadoliberin I -
32	24	1.1	10	1 RHAQ2	gonadoliberin II -
33	24	1.1	10	2 B46030	gonadoliberin II -
34	24	1.1	10	2 A13687	caerulain-like pep
35	24	1.1	10	2 S59625	beta-galactosidase
36	24	1.1	10	2 S23370	T-cell receptor al
37	24	1.1	10	2 A46030	gonadoliberin I -
38	24	1.1	10	2 A21114	gonadoliberin I - ch
39	24	1.1	10	2 E60589	sperm-activating p
40	23.5	1.1	10	2 A31571	hypertrehalosemic/
41	23.5	1.1	10	2 S71948	matrix metalloprot
42	23	1.1	6	2 JU0355	lipopeptide WS1279
43	23	1.1	6	2 PT0532	T-cell receptor be
44	23	1.1	6	2 PD0028	lev-kinin 2 - pena
45	23	1.1	7	2 B33882	cadmium-binding he

ALIGNMENTS

RESULT 1
E48394
glycoprotein component 16/major fat-globule membrane protein/MFG-E8 homolog - bovine (fr
C/Species: Bos primigenius taurus (cattle)
C/Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 07-Feb-1997
C/Accession: E48394
R/Mather, I.H.; Banghart, L.R.; Lane, W.S.
Biochem. Mol. Biol. Int. 29, 545-554, 1993
A/Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig
II-like sequences.
A/Reference number: A48394; MUID:93250576; PMID:8485470
A/Status: preliminary
A/Molecule type: protein
A/Residues: 1-7 <MAT>
A/Experimental source: milk
A/Note: sequence extracted from NCBI backbone (NCBIP.131450)
C/Keywords: glycoprotein

Query Match 1.7%; Score 36; DB 2; Length 7;
Best Local Similarity 85.7%; Pred. No. 2.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 101 WPELAR 107
Db 1 WPELAR 7

RESULT 2
B48394
major fat-globule membrane protein GP 55 - guinea pig (fragment)
C/Species: Cavia porcellus (guinea pig)
C/Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 23-Mar-1995
C/Accession: B48394
R/Mather, I.H.; Banghart, L.R.; Lane, W.S.
Biochem. Mol. Biol. Int. 29, 545-554, 1993
A/Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig
II-like sequences.
A/Reference number: A48394; MUID:93250576; PMID:8485470
A/Status: preliminary
A/Molecule type: protein
A/Residues: 1-7 <MAT>
A/Experimental source: milk
A/Note: sequence extracted from NCBI backbone (NCBIP.131444)

Query Match 1.6%; Score 33; DB 2; Length 7;
Best Local Similarity 85.7%; Pred. No. 2.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 101 WPELAR 107
| | | | |

Db 1 WGPBLAR 7

RESULT 3

H48394

glycoprotein component 16/major fat-globule membrane protein/MFG-E8 homolog - bovine (Fr

C/Species: Bos primigenius taurus (cattle)

C/Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 07-Feb-1997

C/Accession: H48394

R/Mather, I.H.; Banghart, L.R.; Lane, W.S.

Biochem. Mol. Biol. Int. 29, 545-554, 1993

A/Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig

II-like sequences.

A/Reference numbers: A48394; PMID:93250576; PMID:8485470

A/Accession: H48394

A/Status: preliminary

A/Molecule type: protein

A/Residues: 1-6 <MAT>

A/Experimental source: milk

A/Note: sequence extracted from NCBI backbone (NCBIP:131518)

C/Keywords: glycoprotein

Query Match 1.4%; Score 29; DB 2; Length 6;
Best Local Similarity 83.3%; Pred. No. 2.8e+05;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 382 LELLGC 387
Db 1 VELLGC 6

RESULT 4

G60589

sperm-activating peptide (Tyr-2, Asn-3, Asp-7,10, Arg-8, Ile-9 SAP-I) - Echinosmetra mach

C/Species: Echinosmetra machael

C/Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-2004

C/Accession: G60589

R/Yoshino, K.I.; Kajitara, H.; Nomura, K.; Takao, T.; Shimonishi, Y.; Kurita, M.; Yamaguc

Comp. Biochem. Physiol. B 94, 739-751, 1989

A/Title: A halogenated amino acid-containing sperm activating peptide and its related pe

ptus nudus, Echinosmetra machael and Heterocentrotus mammillatus.

A/Reference number: A60527

A/Accession: G60589

A/Molecule type: protein

A/Residues: 1-10 <YOS>

A/Cross-references: UNIPROT:Q7M4C2

Query Match 1.4%; Score 29; DB 2; Length 10;
Best Local Similarity 55.6%; Pred. No. 1e+04;
Matches 5; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 162 YSLNGHEFD 170
Db 2 YNLNGRID 10

RESULT 5

JS0316

leucokinin VI - Madeira cockroach

C/Species: Leucophaea maderae (Madeira cockroach)

C/Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004

C/Accession: JS0316

R/Holman, G.M.; Cook, B.J.; Nachman, R.J.

Comp. Biochem. Physiol. C 88, 27-30, 1987

A/Title: Isolation, primary structure, and synthesis of leucokinin V and VI: myotropic

A/Reference number: JS0315

A/Accession: JS0316

A/Molecule type: protein

A/Residues: 1-8 <HOL>

A/Cross-references: UNIPROT:P19988

C/Comment: Leucokinin, a family of cephalomyotropic peptides, stimulate contractile act

C/Keywords: amidated carboxyl end; cephalomyotropic peptide; pyroglutamic acid

F/1/Modified site: pyroglutamate carboxylic acid (Gln) #status experimental

F/8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 1.3%; Score 28; DB 2; Length 8;
Best Local Similarity 57.1%; Pred. No. 2.8e+05;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 250 SSYKTMG 256
Db 2 SSFHSWG 8

RESULT 6

S65385

Cytochrome-c oxidase (EC 1.9.3.1) chain VIIa, hepatic - rat (fragment)

C/Species: Rattus norvegicus (Norway rat)

C/Date: 12-Feb-1998 #sequence_revision 20-Feb-1998 #text_change 07-May-1999

C/Accession: S65385

R/Schaeffer, H.; Noack, H.; Halangk, W.; Brandt, U.; von Jorgow, G.

Bur. J. Biochem. 230, 235-241, 1995

A/Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and amino-termi

A/Reference number: S65372; PMID:95324529; PMID:7601105

A/Accession: S65385

A/Status: preliminary

A/Molecule type: protein

A/Residues: 1-10 <SCH>

C/Keywords: oxidoreductase

Query Match 1.3%; Score 28; DB 2; Length 10;
Best Local Similarity 57.1%; Pred. No. 1.2e+04;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 239 NSIPDKQ 245
Db 3 NKVPEKQ 9

RESULT 7

B39504

ocmer-binding protein, Ku-like, 83K chain - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 09-Jul-2004

C/Accession: B39504

R/May, G.; Sutton, C.; Gould, H.

J. Biol. Chem. 266, 3052-3059, 1991

A/Title: Purification and characterization of Ku-2, an octamer-binding protein related to

A/Reference number: A39504; PMID:91131605; PMID:1993678

A/Accession: B39504

A/Status: preliminary

A/Molecule type: protein

A/Residues: 1-9 <MAY>

A/Cross-references: UNIPROT:Q7M4Q9

Query Match 1.3%; Score 27; DB 2; Length 9;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 122 NDDNP 126
Db 5 NEDNP 9

RESULT 8

A12872

transaldolase (EC 2.2.1.2) I - yeast (Pichia jadinii) (fragment)

C/Species: Pichia jadinii, Candida utilis

C/Date: 05-Jun-1987 #sequence_revision 05-Jun-1987 #text_change 09-Jul-2004

C/Accession: A12872

R/Sun, S.C.; Joris, L.; Tsolas, O.

Arch. Biochem. Biophys. 178, 69-78, 1977

A/Title: Purification and crystallization of transaldolase isozyme I and evidence for di

A/Reference number: A12872; PMID:77110646; PMID:556924

A/Accession: A12872

A/Molecule type: protein

A/Residues: 1-9 <SUN>
A/Cross-references: UNIPROT:P17440
C/Keywords: transferase

Query Match 1.2%; Score 26; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 2.8e+05;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 63 GNNCET 68
DB 2 GHHCBT 7

RESULT 9

triacylglycerol lipase (EC 3.1.1.3) II - yeast (Geotrichum candidum) (fragments)
C/Species: Geotrichum candidum
C/Date: 31-Dec-1990 #sequence_revision 31-Dec-1990 #text_change 09-Jul-2004
C/Accession: PX0030
R/Sugihara, A.; Shimada, Y.; Tomimaga, Y.
J. Biochem. 107, 426-430, 1990
A/Title: Separation and characterization of two molecular forms of Geotrichum candidum
A/Reference number: PX0030; MUID:90256718; PMID:2341377
A/Accession: PX0030
A/Molecule type: protein
A/Residues: 1-10 <SUG>
A/Cross-references: UNIPROT:P22394
C/Comment: Lipase catalyzes the hydrolysis of triacylglycerols. This fungus contains two
C/Keywords: carboxylic ester hydrolase

Query Match 1.2%; Score 26; DB 2; Length 10;
Best Local Similarity 83.3%; Pred. No. 1.7e+04;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 PRPRLT 7
DB 3 PRPRLT 8

RESULT 10

gut pentapeptide - Japanese eel
JH0253
C/Species: Anguilla japonica (Japanese eel)
C/Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 11-Apr-1995
C/Accession: JH0253
R/Nezaka, T.; Ikeda, T.; Kubota, I.; Muneoka, Y.; Ando, M.
Biochem. Biophys. Res. Commun. 180, 828-832, 1991
A/Title: Structure and function of a pentapeptide isolated from the gut of the eel.
A/Reference number: JH0253; MUID:92062113; PMID:1953755
A/Accession: JH0253
A/Molecule type: protein
A/Residues: 1-5 <UES>
A/Experimental source: gut
C/Comment: This peptide increased basal tone of the circular muscle of the esophagogastric
, and of the circular muscle of the gastro-intestinal junction.

Query Match 1.2%; Score 25; DB 2; Length 5;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 184 GNNMK 188
DB 1 GNNMK 5

RESULT 11

PT0691
T-cell receptor beta chain V-D-J region (154-2K) - mouse (fragment)
C/Species: Mus musculus (house mouse)
C/Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
C/Accession: PT0691
R/Feeney, A.J.
J. Exp. Med. 174, 115-124, 1991

A/Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A/Reference number: PT0509; MUID:91277601; PMID:1711558
A/Accession: PT0691
A/Status: translation not shown

A/Molecule type: DNA
A/Residues: 1-8 <FEF>
A/Experimental source: day 18 fetal thymus, strain BALB/c
C/Keywords: T-cell receptor

Query Match 1.2%; Score 25; DB 2; Length 8;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 335 DPRTG 339
DB 4 EPRTG 8

RESULT 12

acylase - Kluyvera cryocrescens
S19288
C/Species: Kluyvera cryocrescens
C/Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 09-Jul-2004
C/Accession: S19288
R/Martin, J.; Slade, A.; Altken, A.; Arche, R.; Virden, R.
Biochem. J. 280, 659-662, 1991
A/Title: Chemical modification of serine at the active site of penicillin acylase from Kl
A/Reference number: S19288; MUID:92109664; PMID:1764029
A/Accession: S19288
A/Status: preliminary
A/Molecule type: protein
A/Residues: 1-8 <MAR>
A/Cross-references: UNIPROT:Q7M124

Query Match 1.2%; Score 25; DB 2; Length 8;
Best Local Similarity 80.0%; Pred. No. 2.8e+05;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 136 MMVTG 140
DB 3 MMVTG 7

RESULT 13

leucokinin V - Madeira cockroach
JS0315
C/Species: Leucophaea maderae (Madeira cockroach)
C/Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C/Accession: JS0315
R/Holman, G.M.; Cook, B.J.; Nachman, R.J.
Comp. Biochem. Physiol. C 88, 27-30, 1987
A/Title: Isolation, primary structure, and synthesis of leucokinin V and VI: myotropic I
A/Reference number: JS0315
A/Accession: JS0315
A/Molecule type: protein
A/Residues: 1-8 <HOL>
A/Cross-references: UNIPROT:P19987
C/Comment: Leucokinin, a family of cephalomyotropic peptides, stimulate contractile acti
C/Keywords: amidated carboxyl end; cephalomyotropic peptide
F/8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 1.2%; Score 25; DB 2; Length 8;
Best Local Similarity 42.9%; Pred. No. 2.8e+05;
Matches 3; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 250 SSYKWTG 256
DB 2 SSYKWTG 8

RESULT 14

A4117
acetylcholinesterase (EC 3.1.1.7), venom - Asian cobra (fragment)

C;Species: Naja naja oxiana (Asian cobra, Oxus cobra)
 C;Date: 27-Mar-1992 #sequence_revision 27-Mar-1992 #text_change 09-Jul-2004
 C;Accession: A4117
 R;Kreienkamp, H.J.; Weise, C.; Raba, R.; Aaviksaar, A.; Hucho, F.
 Proc. Natl. Acad. Sci. U.S.A. 88, 6117-6121, 1991
 A;Title: Anionic subsites of the catalytic center of acetylcholinesterase from Torpedo
 A;Reference number: A4117; MUID:91296772; PMID:2068091
 A;Accession: A4117
 A;Status: Preliminary
 A;Molecule type: protein
 A;Residues: 1-8 <KRE>
 A;Cross-references: UNIPROT:Q7LZ27
 C;Keywords: carboxylic ester hydrolase

Query Match 1.2%; Score 25; DB 2; Length 8;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 262 WNP8 265
 |||:
 Db 5 WNP8 8

RESULT 15

S07241
 Iltorin - Rohde's leaf frog
 C;Species: Phyllomedusa rohdei (Rohde's leaf frog)
 C;Date: 12-Feb-1993 #sequence_revision 12-Mar-1993 #text_change 09-Jul-2004
 C;Accession: S07241
 R;Barra, D.; Falconieri Erspaner, G.; Simmaco, M.; Bossa, F.; Melchiorri, P.; Erspaner,
 FEBS Lett. 182, 53-56, 1985
 A;Title: Rohdei-iltorin: a new peptide from the skin of Phyllomedusa rohdei.
 A;Reference number: S07241; MUID:85127560; PMID:3838283
 A;Accession: S07241
 A;Molecule type: protein
 A;Residues: 1-9 <BAR>
 A;Cross-references: UNIPROT:P08946
 C;Superfamily: gastrin-releasing peptide
 C;Keywords: amidated carboxyl end; blocked amino end; neuropeptide; pyroglutamic acid
 F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
 F;9/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 1.2%; Score 25; DB 2; Length 9;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 135 RMWVG 140
 ::|||
 Db 1 QLMATG 6

Search completed: January 24, 2005, 14:46:21
 Job time : 40 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 24, 2005, 14:36:22 ; Search time 142 Seconds
(without alignments)
984.641 Million cell updates/sec

Title: US-09-744-804A-78

Perfect score: 2110

Sequence: 1 MRPRLALCGALCAPSL.....RIPVAMHRLRLLELGC 387

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1608061 seqs, 361289386 residues

Total number of hits satisfying chosen parameters: 184693

Minimum DB seq length: 0

Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications_AA:*
1: /cgn2_6/ptodata/1/pubppa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubppa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubppa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubppa/US07_NEW_PUB.pep:*
5: /cgn2_6/ptodata/1/pubppa/US08_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubppa/US09_NEW_PUB.pep:*
7: /cgn2_6/ptodata/1/pubppa/US10_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubppa/US11_NEW_PUB.pep:*
9: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.pep:*
13: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.pep:*
17: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.pep:*
18: /cgn2_6/ptodata/1/pubppa/US11_NEW_PUB.pep:*
19: /cgn2_6/ptodata/1/pubppa/US60_NEW_PUB.pep:*
20: /cgn2_6/ptodata/1/pubppa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	48	2.3	9	US-10-006-177-19
2	44	2.1	9	US-09-865-548A-43
3	41	1.9	8	US-10-235-852-19
4	39	1.8	8	US-09-908-322-88
5	39	1.8	8	US-09-908-322-88
6	35	1.7	9	US-10-743-931-88
7	35	1.7	9	US-10-743-931-88
8	35	1.7	9	US-10-743-931-88
9	34	1.6	8	US-09-947-925A-29
10	34	1.6	9	US-10-083-768-69
11	34	1.6	9	US-10-393-269-38
12	34	1.6	9	US-10-774-176-16
13	34	1.6	10	US-09-935-430-433

14	34	1.6	10	US-09-809-638-585	Sequence 585, App
15	34	1.6	10	US-09-809-638-585	Sequence 680, App
16	34	1.6	10	US-09-563-223-34	Sequence 34, App
17	34	1.6	10	US-10-083-768-63	Sequence 63, App
18	34	1.6	10	US-10-277-292-433	Sequence 433, App
19	34	1.6	10	US-10-280-340-433	Sequence 46, App
20	34	1.6	10	US-10-609-217-46	Sequence 46, App
21	34	1.6	10	US-10-632-388-46	Sequence 46, App
22	34	1.6	10	US-10-651-723-46	Sequence 46, App
23	34	1.6	10	US-10-645-761-46	Sequence 46, App
24	34	1.6	10	US-10-666-696-46	Sequence 46, App
25	34	1.6	10	US-10-653-048-46	Sequence 46, App
26	34	1.6	10	US-10-783-950-34	Sequence 123, App
27	33	1.6	9	US-09-935-430-123	Sequence 123, App
28	33	1.6	9	US-09-935-430-123	Sequence 123, App
29	33	1.6	9	US-10-277-292-123	Sequence 123, App
30	33	1.6	9	US-10-277-292-123	Sequence 123, App
31	33	1.6	9	US-10-280-340-123	Sequence 123, App
32	33	1.6	9	US-10-280-340-216	Sequence 126, App
33	33	1.6	9	US-10-182-252A-190	Sequence 190, App
34	33	1.6	9	US-10-415-014-131	Sequence 331, App
35	33	1.6	10	US-09-572-404B-422	Sequence 422, App
36	33	1.6	10	US-09-572-404B-567	Sequence 567, App
37	33	1.6	10	US-09-572-404B-569	Sequence 569, App
38	33	1.6	10	US-09-572-404B-1017	Sequence 1017, App
39	33	1.6	10	US-10-083-768-122	Sequence 122, App
40	33	1.6	10	US-10-271-343-46	Sequence 46, App
41	33	1.6	10	US-10-440-479-6	Sequence 6, App
42	33	1.6	10	US-10-415-014-381	Sequence 381, App
43	33	1.6	10	US-10-654-578-1098	Sequence 1098, App
44	33	1.6	10	US-10-654-578-1370	Sequence 1370, App
45	32	1.5	7	US-10-442-880-1	Sequence 1, App

ALIGNMENTS

RESULT 1
US-10-006-177-19
Sequence 19, Application US/10006177
Publication No. US20030165513A1
GENERAL INFORMATION:
APPLICANT: Ramakrishna, Venky
APPLICANT: Ross, Mark
TITLE OF INVENTION: Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatme
FILE REFERENCE: 26747-35
CURRENT FILING DATE: 2001-12-04
PRIOR APPLICATION NUMBER: US/10/006,177
PRIOR FILING DATE: 2000-12-04
PRIOR APPLICATION NUMBER: US/60/251,022
PRIOR FILING DATE: 2000-12-04
PRIOR APPLICATION NUMBER: US/60/256,824
PRIOR FILING DATE: 2000-12-20
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn version 3.0
SEQ ID NO 19
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Epitopic Peptide
US-10-006-177-19

Query Match 2.3%; Score 48; DB 14; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 152 HEYTKAFV 160
DB 1 HEYTKAFV 9

RESULT 2
US-09-865-548A-43
; Sequence 43, Application US/09865548A
; Publication No. US20030096298A1
; GENERAL INFORMATION:
; APPLICANT: Barnea, Eilon
; APPLICANT: Beer, Ilan
; APPLICANT: Ziv, Tamar
; APPLICANT: Admon, Arie
; TITLE OF INVENTION: METHOD OF IDENTIFYING PEPTIDES CAPABLE OF BINDING TO MHC MOLECULE
; TITLE OF INVENTION: PEPTIDES IDENTIFIED THEREBY AND THEIR USES
; FILE REFERENCE: 01/22080
; CURRENT APPLICATION NUMBER: US/09/865,548A
; CURRENT FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: US 60/290,958
; PRIOR FILING DATE: 2001-05-16
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 43
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-09-865-548A-43

Query Match 2.1%; Score 44; DB 10; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 ALICAPSL 21
DB 1 ALICAPSL 9

RESULT 3
US-10-235-852-19
; Sequence 19, Application US/10235852
; Publication No. US20040052928A1
; GENERAL INFORMATION:
; APPLICANT: Gazit, Ehud
; TITLE OF INVENTION: PEPTIDES AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLO
; TITLE OF INVENTION: ASSOCIATED DISEASES
; FILE REFERENCE: 02/23654
; CURRENT APPLICATION NUMBER: US/10/235,852
; CURRENT FILING DATE: 2002-09-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 19
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: lactadherin derived, active site sequence
US-10-235-852-19

Query Match 1.9%; Score 41; DB 15; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.5e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 309 NFGSVQFV 316
DB 1 NFGSVQFV 8

RESULT 4
US-09-908-322-88
; Sequence 88, Application US/09908322
; Patent No. US20020107194A1
; GENERAL INFORMATION:
; APPLICANT: Ish-Horowicz, David
; Henriques, Domingos Manuel Pinto
; Lewis, Julian Hart

Artavanis-Tsakonas, Spyridon
Gray, Grace
TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES OF
VERTEBRATE DELTA GENE AND METHODS BASED THEREON
NUMBER OF SEQUENCES: 94
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/908,322
FILING DATE: 17-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/981,392
FILING DATE: 22-DEC-1997
ATTORNEY/AGENT INFORMATION:
NAME: Mastrock, S Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7326-123
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIS
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: unknown
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 88:
US-09-908-322-88

Query Match 1.8%; Score 39; DB 9; Length 8;
Best Local Similarity 85.7%; Pred. No. 1.5e+06;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNG 36
DB 1 NPCHNG 7

RESULT 5
US-09-783-931-88
; Sequence 88, Application US/09783931
; Publication No. US20030073620A1
; GENERAL INFORMATION:
; APPLICANT: Ish-Horowicz, David
; Henriques, Domingos Manuel Pinto
; Lewis, Julian Hart
; Artavanis-Tsakonas, Spyridon
; Gray, Grace
TITLE OF INVENTION: ANTIBODIES TO VERTEBRATE DELTA PROTEINS
AND FRAGMENTS
NUMBER OF SEQUENCES: 94
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/783,931
FILING DATE: 15-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/981,392
FILING DATE: 22-DEC-1997
ATTORNEY/AGENT INFORMATION:
NAME: Antler, Adriane M.
REGISTRATION NUMBER: 32,605
REFERENCE/DOCKET NUMBER: 7326-122
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: unknown
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 88:
US-09-783-931-88

Query Match 1.7%; Score 35; DB 10; Length 9;
Best Local Similarity 85.7%; Pred. No. 1.5e+06;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPGCHG 36
DB 1 NPGCHG 7

RESULT 6
US-10-743-649-6
Sequence 6, Application US/10743649
Publication No. US20040170607A1
GENERAL INFORMATION:
APPLICANT: PRO-VIRUS, INC.
TITLE OF INVENTION: ONCOLYTIC VIRUS
FILE REFERENCE: 2370-63
CURRENT APPLICATION NUMBER: US/10/743,649
CURRENT FILING DATE: 2003-12-22
PRIOR APPLICATION NUMBER: US/09/664,444
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: 09/397,873
PRIOR FILING DATE: 1999-09-17
NUMBER OF SEQ ID NOS: 52
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-743-649-6

Query Match 1.7%; Score 35; DB 16; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.5e+06;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 348 WDNHSH 353
DB 2 WDNHSH 7

RESULT 7
US-10-743-639-6

Sequence 6, Application US/10743639
Publication No. US20040208849A1
GENERAL INFORMATION:
APPLICANT: PRO-VIRUS, INC.
TITLE OF INVENTION: ONCOLYTIC VIRUS
FILE REFERENCE: 2370-63
CURRENT APPLICATION NUMBER: US/10/743,639
CURRENT FILING DATE: 2003-12-22
PRIOR APPLICATION NUMBER: US/09/664,444
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: 09/397,873
PRIOR FILING DATE: 1999-09-17
NUMBER OF SEQ ID NOS: 52
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-743-639-6

Query Match 1.7%; Score 35; DB 17; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.5e+06;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 348 WDNHSH 353
DB 2 WDNHSH 7

RESULT 8
US-09-572-404B-3564
Sequence 3564, Application US/09572404B
Publication No. US20030078374A1
GENERAL INFORMATION:
APPLICANT: Proteom Ltd
TITLE OF INVENTION: Complementary peptide ligands from the human genome
FILE REFERENCE: Human patent
CURRENT APPLICATION NUMBER: US/09/572,404B
CURRENT FILING DATE: 2000-05-17
NUMBER OF SEQ ID NOS: 4203
SOFTWARE: ProPatent version 1.0
SEQ ID NO 3564
LENGTH: 10
TYPE: PRT
ORGANISM: Homo Sapiens
FEATURE:
OTHER INFORMATION: sequence located in NID2 at 780-789 and may interact with Sequence
US-09-572-404B-3564

Query Match 1.7%; Score 35; DB 10; Length 10;
Best Local Similarity 83.3%; Pred. No. 1.4e+04;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 52 SYTCTC 57
DB 5 SYTCTC 10

RESULT 9
US-09-947-925A-29
Sequence 29, Application US/09947925A
Patent No. US20020055482A1
GENERAL INFORMATION:
APPLICANT: Huber, Brian
TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic
TITLE OF INVENTION: Antigen Regulatory
FILE REFERENCE: PB1087US3

CURRENT APPLICATION NUMBER: US/09/947,925A
CURRENT FILING DATE: 2001-09-06
PRIOR APPLICATION NUMBER: US/08/154,712
PRIOR FILING DATE: 1993-11-19
NUMBER OF SEQ ID NOS: 36
SOFTWARE: PatentIn version 3.0
SEQ ID NO 29
LENGTH: 8
TYPE: PRT
ORGANISM: Consensus sequence
FEATURE:
NAME/KEY: misc.feature
OTHER INFORMATION: Consensus sequence f6 from transcriptional dictionary
OTHER INFORMATION: of Locker a
OTHER INFORMATION: nd Buzard (1990).
US-09-947-925A-29

Query Match
Best Local Similarity 71.4%; Score 34; DB 9; Length 8;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCONTACT 217
:|||||
1 CONTACT 7

RESULT 10
US-10-083-768-69
Sequence 69, Application US/10083768
Publication No. US20030158116A1
GENERAL INFORMATION:
APPLICANT: Dower, William J.
Barrett, Ronald W.
Cwifla, Steven E.
Duffin, David J.
Gates, Christian
Haselden, Sherri L.
Matheakis, Larry C.
Schatz, Peter J.
Wagstrom, Christopher R.
Wrighton, Nicholas C.
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
THROMBOPOIETIN RECEPTOR
NUMBER OF SEQUENCES: 232
CORRESPONDENCE ADDRESS:
ADDRESSEE: Glaxo Wellcome
STREET: Five Moore Drive, P.O. Box 13398
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/083,768
FILING DATE: 27-Feb-2002
ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PR3065USW
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:

US-10-083-768-69

Query Match
Best Local Similarity 46.7%; Score 34; DB 14; Length 9;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTRPBLGCEINGC 230
|||||
1 CTRPBLGCEINGC 230

RESULT 11
US-10-393-269-38
Sequence 38, Application US/10393269
Publication No. US20030223979A1
GENERAL INFORMATION:
APPLICANT: GELBERFORS, Par
APPLICANT: FOGH, Jens
TITLE OF INVENTION: NEW THERAPEUTIC METHOD FOR TREATING PATIENTS WITH ACUTE
TITLE OF INVENTION: INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC
DISEASES
FILE REFERENCE: GELBERFORS-1A
CURRENT APPLICATION NUMBER: US/10/393,269
PRIOR APPLICATION NUMBER: US/09/358,856C
PRIOR FILING DATE: 1999-07-22
NUMBER OF SEQ ID NOS: 40
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 38
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: encoded by
US-10-393-269-38

Query Match
Best Local Similarity 57.1%; Score 34; DB 14; Length 9;
Matches 4; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 372 VAMHNR 378
:|||||
3 MGVHNRV 9

RESULT 12
US-10-774-176-16
Sequence 16, Application US/10774176
Publication No. US20040265275A1
GENERAL INFORMATION:
APPLICANT: CARROLL, MILES WILLIAM
APPLICANT: MYERS, KEVIN ALAN
TITLE OF INVENTION: POLYPEPTIDE
FILE REFERENCE: 078883/0120
CURRENT APPLICATION NUMBER: US/10/774,176
CURRENT FILING DATE: 2004-02-06
PRIOR APPLICATION NUMBER: US/09/533,798
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: 60/126,187
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: 60/126,188
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: GB 9825303.2
PRIOR FILING DATE: 1998-11-18
PRIOR APPLICATION NUMBER: GB 9901739.4
PRIOR FILING DATE: 1999-01-27
PRIOR APPLICATION NUMBER: GB 9917995.4
PRIOR FILING DATE: 1999-07-30
NUMBER OF SEQ ID NOS: 27
SOFTWARE: PatentIn version 2.1
SEQ ID NO 16
LENGTH: 9

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 574 9 Mer
US-10-774-176-16
```

```
Query Match 1.6%; Score 34; DB 17; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.5e+06;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 123 DDNPWT 128
DB 3 DNNPMV 8
```

```
RESULT 13
US-09-935-430-433
; Sequence 433, Application US/09935430
; Publication No. US20030017466A1
; GENERAL INFORMATION:
```

```
; APPLICANT: FARIS, MARY
; APPLICANT: HUBERT, RENE
; APPLICANT: RAITANO, ARTHUR
; APPLICANT: AFAR, DANIEL
; APPLICANT: LEVIN, ELANA
; APPLICANT: CHALLITA-EID, PIA
; APPLICANT: JAKOBOVITS, AVA
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7
; TITLE OF INVENTION: USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND
; TITLE OF INVENTION: OTHER CANCERS
; FILE REFERENCE: 51158-20050.00
; CURRENT APPLICATION NUMBER: US/09/935,430
; CURRENT FILING DATE: 2001-08-22
; PRIOR APPLICATION NUMBER: 60/227,098
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/282,739
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 700
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 433
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Peptide motif
US-09-935-430-433
```

```
Query Match 1.6%; Score 34; DB 10; Length 10;
Best Local Similarity 50.0%; Pred. No. 1.7e+04;
Matches 5; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 96 LGLOHVVPEL 105
DB 1 VGLQOWIOKL 10
```

```
RESULT 14
US-09-809-638-585
; Sequence 585, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
; APPLICANT: Mary Faris
; APPLICANT: Pia M. Challita-Eid
; APPLICANT: Steve Chappell Mitchell
; APPLICANT: Daniel E.H. Afar
; APPLICANT: Arthur B. Raitano
; APPLICANT: Aya Jakobovits
; TITLE OF INVENTION: 125P5C8: A TISSUE SPECIFIC PROTEIN
; TITLE OF INVENTION: HIGHLY EXPRESSED IN VARIOUS CANCERS
; FILE REFERENCE: 129.35US01
; CURRENT APPLICATION NUMBER: US/09/809,638
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 746
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 585
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-809-638-585
```

```
Query Match 1.6%; Score 34; DB 10; Length 10;
Best Local Similarity 55.6%; Pred. No. 1.7e+04;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 249 SSSYKTWGL 257
DB 1 STRYHTWGI 9
```

```
RESULT 15
US-09-809-638-680
; Sequence 680, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Mary Faris
; APPLICANT: Pia M. Challita-Eid
; APPLICANT: Steve Chappell Mitchell
; APPLICANT: Daniel E.H. Afar
; APPLICANT: Arthur B. Raitano
; APPLICANT: Aya Jakobovits
; TITLE OF INVENTION: 125P5C8: A TISSUE SPECIFIC PROTEIN
; TITLE OF INVENTION: HIGHLY EXPRESSED IN VARIOUS CANCERS
; FILE REFERENCE: 129.35US01
; CURRENT APPLICATION NUMBER: US/09/809,638
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 746
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 680
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-809-638-680
```

```
Query Match 1.6%; Score 34; DB 10; Length 10;
Best Local Similarity 55.6%; Pred. No. 1.7e+04;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 249 SSSYKTWGL 257
DB 1 STRYHTWGI 9
```

```
Search completed: January 24, 2005, 14:44:51
Job time : 144 secs
```

This Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 24, 2005, 14:36:23 ; Search time 40 Seconds
(without alignments)
641.627 Million cell updates/sec

Title: US-09-744-804A-78

Sequence: 1 MRPRLALALGALCAPSL.....RILPVAHNRILRLLELLG 387

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 110780

Minimum DB seq length: 0
Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/prodata/1/aa/5A COMB.pep.*
2: /cgn2_6/prodata/1/aa/5B COMB.pep.*
3: /cgn2_6/prodata/1/aa/6A COMB.pep.*
4: /cgn2_6/prodata/1/aa/6B COMB.pep.*
5: /cgn2_6/prodata/1/aa/PCTUS COMB.pep.*
6: /cgn2_6/prodata/1/aa/backfile1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	42	2.0	9	1	US-08-179-481-115
2	42	2.0	10	6	5177197-8
3	39	1.8	8	3	US-08-981-392-88
4	39	1.8	8	4	US-09-908-322-88
5	37	1.8	10	1	US-08-179-481-31
6	36	1.7	7	2	US-08-162-4028-23
7	34	1.6	8	3	US-08-481-968A-29
8	34	1.6	8	3	US-08-154-7128-29
9	34	1.6	8	4	US-09-947-925A-29
10	34	1.6	9	2	US-08-764-640-69
11	34	1.6	9	3	US-08-973-225-69
12	34	1.6	9	3	US-09-244-298A-69
13	34	1.6	9	3	US-09-516-704-69
14	34	1.6	9	4	US-09-549-090-69
15	34	1.6	9	4	US-09-832-230A-69
16	34	1.6	9	4	US-09-358-856C-38
17	34	1.6	10	2	US-08-764-640-63
18	34	1.6	10	2	US-08-556-597-121
19	34	1.6	10	3	US-08-973-225-63
20	34	1.6	10	3	US-09-244-298A-63
21	34	1.6	10	3	US-09-516-704-63
22	34	1.6	10	4	US-09-549-090-63
23	34	1.6	10	4	US-09-832-230A-63
24	34	1.6	10	4	US-09-428-0828-46
25	34	1.6	10	4	US-09-563-222C-34
26	33	1.6	7	2	US-08-162-4028-22
27	33	1.6	9	2	US-08-290-268-10

28	33	1.6	10	2	US-08-764-640-122	Sequence 122, App
29	33	1.6	10	2	US-08-335-832-8	Sequence 8, Appl
30	33	1.6	10	3	US-09-141-127-2	Sequence 2, Appl
31	33	1.6	10	3	US-08-973-225-122	Sequence 122, App
32	33	1.6	10	3	US-09-244-298A-122	Sequence 122, App
33	33	1.6	10	3	US-09-516-704-122	Sequence 122, App
34	33	1.6	10	4	US-09-549-090-122	Sequence 122, App
35	33	1.6	10	4	US-09-832-230A-122	Sequence 122, App
36	33	1.6	10	4	US-09-535-852-1098	Sequence 1098, Ap
37	33	1.6	10	4	US-09-535-852-1370	Sequence 1370, Ap
38	32	1.5	7	4	US-09-599-846-1	Sequence 1, Appl
39	32	1.5	7	6	5256643-5	Patent No. 5256643
40	32	1.5	9	1	US-07-646-531D-4	Sequence 4, Appl
41	32	1.5	9	1	US-07-646-531D-19	Sequence 19, Appl
42	32	1.5	9	2	US-08-488-273-4	Sequence 4, Appl
43	32	1.5	9	3	US-08-142-590B-10	Sequence 10, Appl
44	32	1.5	9	3	US-09-139-802-113	Sequence 113, App
45	32	1.5	9	3	US-09-197-770B-10	Sequence 10, Appl

ALIGNMENTS

RESULT 1
US-08-179-481-115
; Sequence 115, Application US/08179481
; Patent No. 5624816
; GENERAL INFORMATION:
; APPLICANT: CARRAWAY, KERMIT L.
; APPLICANT: CAROTHERS CARRAWAY, CORALIE A.
; APPLICANT: FREGIEN, NEVIS L.
; TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND
; NUMBER OF SEQUENCES: 125
; CORRESPONDENCE ADDRESS: 125
; ADDRESSES: CUSHMAN, DARBY & CUSHMAN
; STREET: 1100 NEW YORK AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/179,481
; FILING DATE: 28-DEC-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/922,521
; FILING DATE: 30-JUL-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 861-3000
; TELEFAX: (202) 822-0944
; TELEX: 6714627 CUSH
; INFORMATION FOR SEQ ID NO: 115:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-179-481-115

Query Match 2.0%; Score 42; DB 1; Length 9;
Best Local Similarity 85.7%; Pred. No. 3.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 32 CHNGGLC 38
DB 3 CHNGGOC 9

RESULT 2

5177197-8
PATENT NO. 5177197
APPLICANT: KANZAKI, TETSUO; OLOFSSON, ANDERS; MOREN, ANITA;
WERNSTEDT, CHRISTER; HELLMAN, ULF; MIYAZONO, KOHEI; CLASSON-WELSH,
LENA; HELDIN, CARL-HENRIK
TITLE OF INVENTION: ISOLATED NUCLEOTIDE SEQUENCE EXPRESSING
HUMAN TRANSFORMING GROWTH FACTOR-BETA1-BINDING PROTEIN
NUMBER OF SEQUENCES: 53
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/487,343
FILING DATE: 27-FEB-1990
SEQ ID NO: 8
LENGTH: 10
5177197-8

Query Match 2.0%; Score 42; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 7.9e+02;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 53 YTCCTCLKGY 61
DB 1 YTCCTCLKGY 9

RESULT 3

US-08-981-392-88
SEQUENCE 88, APPLICATION US/08981392
PATENT NO. 6262025
GENERAL INFORMATION:
APPLICANT: Ish-Horowitz, David
APPLICANT: Henrique, Domingos Manuel Pinto
APPLICANT: Lewis, Julian Hart
APPLICANT: Artavakis-Tsakonas, Spyridon
APPLICANT: Gray, Grace
TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES
TITLE OF INVENTION: OF VERTEBRATE DELTA GENES AND METHODS BASED THEREON
NUMBER OF SEQUENCES: 94
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/981,392
FILING DATE: 22-DEC-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Antler, Adriane M.
REGISTRATION NUMBER: 32,605
REFERENCE/DOCKET NUMBER: 7326-038
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: unknown

MOLECULE TYPE: peptide
US-08-981-392-88

Query Match 1.8%; Score 39; DB 3; Length 8;
Best Local Similarity 85.7%; Pred. No. 3.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNGG 36
DB 1 NPCKNGG 7

RESULT 4
US-09-908-322-88
SEQUENCE 88, APPLICATION US/09908322
PATENT NO. 6783956
GENERAL INFORMATION:
APPLICANT: Ish-Horowitz, David
Henrique, Domingos Manuel Pinto
Lewis, Julian Hart
Artavakis-Tsakonas, Spyridon
Gray, Grace

TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES OF
VERTEBRATE DELTA GENE AND METHODS BASED THEREON
NUMBER OF SEQUENCES: 94
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds LLP
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036/2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/908,322
FILING DATE: 17-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/981,392
FILING DATE: 22-DEC-1997

ATTORNEY/AGENT INFORMATION:
NAME: Mirock, S Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 7326-123
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: unknown
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 88:

US-09-908-322-88

Query Match 1.8%; Score 39; DB 4; Length 8;
Best Local Similarity 85.7%; Pred. No. 3.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNGG 36
DB 1 NPCKNGG 7

RESULT 5
US-08-179-481-31

Sequence 31, Application US/08179481
Patent No. 5624816
GENERAL INFORMATION:
APPLICANT: CARRAWAY, KERMIT L.
APPLICANT: CAROTHERS, CARRAWAY, CORALIE A.
APPLICANT: FREIGEN, NEVIS L.
TITLE OF INVENTION: ONCOGENE PRODUCT LIGAND
NUMBER OF SEQUENCES: 125
CORRESPONDENCE ADDRESS:
ADDRESSEE: CUSHMAN, DARBY & CUSHMAN
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005-3918
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/179,481
FILING DATE: 28-DEC-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/922,521
FILING DATE: 30-JUL-1992
ATTORNEY/AGENT INFORMATION:
NAME: KOKULIS, PAUL N.
REGISTRATION NUMBER: 16,773
REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 861-3000
TELEFAX: (202) 822-0944
TELEX: 6714627 CUSH
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-179-481-31

Query Match 1.8%; Score 37; DB 1; Length 10;
Best Local Similarity 85.7%; Pred. No. 2.3e+03;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 NPCHNG 36
DB 3 NPCLNG 9

RESULT 6
US-08-162-402B-23
Sequence 23, Application US/08162402B
Patent No. 5972337
GENERAL INFORMATION:
APPLICANT: CERTANT, ROBERTO L.
APPLICANT: PETERSON, JERRY A.
APPLICANT: LAROSCA, DAVID J.
TITLE OF INVENTION: 46 KDALTON HUMAN MILK FAT
TITLE OF INVENTION: GLOBULE (HMEG) ANTIGEN, FRAGMENTS & FUSION PROTEIN
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pretty, Schroeder & Poplawski
STREET: 444 South Flower St., 19th Floor
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/162,402B
FILING DATE: 03-DEC-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: P66 38215
TELECOMMUNICATION INFORMATION:
TELEPHONE: 213-622-7700
TELEFAX: 213-489-4210
TELEX:
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 7 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-162-402B-23

Query Match 1.7%; Score 36; DB 2; Length 7;
Best Local Similarity 85.7%; Pred. No. 3.8e+05;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 WVEPLAR 107
DB 1 WVEPLAR 7

RESULT 7
US-08-481-968A-29
Sequence 29, Application US/08481968A
Patent No. 6300490
GENERAL INFORMATION:
APPLICANT: Huber, Brian
APPLICANT: Richards, Cynthia
TITLE OF INVENTION: Molecular Constructs Comprising a Carcinoembryonic Antigen (CEA)
TITLE OF INVENTION: Transcriptional Regulatory Region
FILE REFERENCE: PB1087US4
CURRENT APPLICATION NUMBER: US/08/481,968A
CURRENT FILING DATE: 1998-06-07
NUMBER OF SEQ ID NOS: 36
SOFTWARE: Patent in version 3.0
SEQ ID NO 29
LENGTH: 8
TYPE: PRT
ORGANISM: Consensus sequence
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Consensus sequence P6 from transcriptional dictionary of Locker a
US-08-481-968A-29

Query Match 1.6%; Score 34; DB 3; Length 8;
Best Local Similarity 71.4%; Pred. No. 3.8e+05;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHTACT 217
DB 1 TCVNACT 7

RESULT 8
US-08-154-712B-29
Sequence 29, Application US/08154712B
Patent No. 6337209

```

; GENERAL INFORMATION:
; APPLICANT: Huber, Brian
; APPLICANT: Richards, Cynthia
; TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic Antigen Regu
; TITLE OF INVENTION: Sequence
; FILE REFERENCE: PB1087US3
; CURRENT APPLICATION NUMBER: US/08/154,712B
; CURRENT FILING DATE: 1993-11-19
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Consensus sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Consensus sequence F6 from transcriptional dictionary of Locker a
; OTHER INFORMATION: nd Buzard (1990).
; US-08-154-712B-29

Query Match 1.6%; Score 34; DB 3; Length 8;
Best Local Similarity 71.4%; Pred. No. 3.8e+05;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHATZ 217
Db 1 TCNTACT 7

RESULT 9
US-09-947-925A-29
; Sequence 29, Application US/09947925A
; Patent No. 6699690
; GENERAL INFORMATION:
; APPLICANT: Huber, Brian
; APPLICANT: Richards, Cynthia
; TITLE OF INVENTION: Molecular Constructs Containing a Carcinoembryonic
; TITLE OF INVENTION: Antigen Regulatory
; TITLE OF INVENTION: Sequence
; FILE REFERENCE: PB1087US3
; CURRENT APPLICATION NUMBER: US/09/947,925A
; CURRENT FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: US/08/154,712
; PRIOR FILING DATE: 1993-11-19
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Consensus sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Consensus sequence F6 from transcriptional dictionary
; OTHER INFORMATION: of Locker a
; OTHER INFORMATION: nd Buzard (1990).
; US-09-947-925A-29

Query Match 1.6%; Score 34; DB 4; Length 8;
Best Local Similarity 71.4%; Pred. No. 3.8e+05;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 211 SCHATZ 217
Db 1 TCNTACT 7

RESULT 10
US-08-764-640-69
; Sequence 69, Application US/08764640
; Patent No. 5869451
; Patent No. 5869451 5837683
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
```

```

; APPLICANT: Barrett, Ronald W.
; APPLICANT: Cwiria, Steven E.
; APPLICANT: Gates, Christian
; APPLICANT: Schatz, Peter J.
; APPLICANT: Balasubramanian, Palaniappan
; APPLICANT: Wagstrom, Christopher R.
; APPLICANT: Hendren, Richard R.
; APPLICANT: Depirnce, Randolph B.
; APPLICANT: Podatuturi, Surekha
; APPLICANT: Yin, Qun
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: RECEPTOR
; NUMBER OF SEQUENCES: 244
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Glaxo Wellcome
; STREET: Five Moore Drive, P.O. Box 13398
; CITY: Research Triangle Park
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,640
; FILING DATE: 11-DEC-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrudienc, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-764-640-69

Query Match 1.6%; Score 34; DB 2; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTIRFELGELNGC 230
Db 1 CTLEF-----MNGC 9

RESULT 11
US-08-973-225-69
; Sequence 69, Application US/08973225A
; Patent No. 6083913
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Cwiria, Steven E.
; APPLICANT: Duffin, David J.
; APPLICANT: Gates, Christian
; APPLICANT: Haselden, Sherril S.
; APPLICANT: Matheakis, Larry C.
; APPLICANT: Schatz, Peter J.
; APPLICANT: Wagstrom, Christopher R.
; APPLICANT: Wrighton, Nicholas C.
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: THROMBOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 232
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Glaxo Wellcome
```

STREET: Five Moore Drive, P.O. Box 13398
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/973,225A
FILING DATE: 04-Dec-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PK3065USW
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-08-973-225-69

Query Match 1.6%; Score 34; DB 3; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTLPFLGCELNGC 230
DB 1 CTLEF-----MNGC 9

RESULT 12
US-09-244-298a-69
Sequence 69, Application US/09244298A
Patent No. 6121238
GENERAL INFORMATION:
APPLICANT: Dower, William J.
APPLICANT: Barrett, Ronald W.
APPLICANT: Cwiria, Steven E.
APPLICANT: Gates, Christian
APPLICANT: Schatz, Peter J.
APPLICANT: Balasubramanian, Palaniappan
APPLICANT: Magstrom, Christopher R.
APPLICANT: Hendren, Richard W.
APPLICANT: Deprince, Randolph B.
APPLICANT: Podduturi, Surekha
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
RECEPTOR
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 244
FILING DATE: 01-Mar-2000
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PK3281
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-244-298a-69

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/244,298A
FILING DATE: 11-DEC-1996
CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PK3281
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-244-298a-69

Query Match 1.6%; Score 34; DB 3; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

QY 216 CTLPFLGCELNGC 230
DB 1 CTLEF-----MNGC 9

RESULT 13
US-09-516-704-69
Sequence 69, Application US/09516704
Patent No. 6251864
GENERAL INFORMATION:
APPLICANT: Dower, William J.
APPLICANT: Barrett, Ronald W.
APPLICANT: Cwiria, Steven E.
APPLICANT: Gates, Christian
APPLICANT: Schatz, Peter J.
APPLICANT: Balasubramanian, Palaniappan
APPLICANT: Magstrom, Christopher R.
APPLICANT: Hendren, Richard W.
APPLICANT: Deprince, Randolph B.
APPLICANT: Podduturi, Surekha
TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
RECEPTOR
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 244
FILING DATE: 01-Mar-2000
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PK3281
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-516-704-69

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/516,704
FILING DATE: 01-Mar-2000
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Hrubiec, Robert T.
REGISTRATION NUMBER: 36,392
REFERENCE/DOCKET NUMBER: PK3281
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-516-704-69

Query Match 1.6%; Score 34; DB 3; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230
DB 1 CTRF-----MNGC 9

RESULT 14
US-09-549-090-69
; Sequence 69, Application US/09549090
; Patent No. 6465430
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; Barrett, Ronald W.
; Cwila, Steven E.
; Duffin, David J.
; Gates, Christian
; Haselden, Sherril S.
; Matheakis, Larry C.
; Schatz, Peter J.
; Wagstrom, Christopher R.
; Wrighton, Nicholas C.
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; WRIGHTON, NICHOLAS C.
; NUMBER OF SEQUENCES: 232
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Glaxo Wellcome
; STREET: Five Moore Drive, P.O. Box 13398
; CITY: Research Triangle Park
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/549,090
; FILING DATE: 13-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/973,225
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrubiec, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3065USW
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-549-090-69

Query Match 1.6%; Score 34; DB 4; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230
DB 1 CTRF-----MNGC 9

RESULT 15
US-09-832-230A-69

; Sequence 69, Application US/09832230A
; Patent No. 6506362
; GENERAL INFORMATION:
; APPLICANT: Dower, William J et al
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; RECEPTOR
; NUMBER OF SEQUENCES: 244
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Glaxo Wellcome
; STREET: Five Moore Drive, P.O. Box 13398
; CITY: Research Triangle Park
; STATE: NC
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/832,230A
; FILING DATE: 10-Apr-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Hrubiec, Robert T.
; REGISTRATION NUMBER: 36,392
; REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 69:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 69:
US-09-832-230A-69

Query Match 1.6%; Score 34; DB 4; Length 9;
Best Local Similarity 46.7%; Pred. No. 3.8e+05;
Matches 7; Conservative 1; Mismatches 1; Indels 6; Gaps 1;

OY 216 CTRFELLGCEINGC 230
DB 1 CTRF-----MNGC 9

Search completed: January 24, 2005, 14:45:43
Job time : 48 secs